Pharma has a familiar playbook: take an old drug, reframe the story, and charge like it’s new.
In a world where patients, payers, and policymakers are increasingly focused on value—not just volume—repurposed medicines are becoming the latest battlegrou…

Pharma hiring is broken in a very specific way.
Recruiters often chase the loudest signals—titles, conference buzz, “brand-name” employers—while quietly ignoring the most reliable map of scientific influence: patent citations.
If you’re trying to find …

Pharma has a new way to tell the same story: “It’s not a new drug—it’s a new value proposition.”
That’s the subtext behind the latest wave of premium pricing for repurposed medicines—older compounds reintroduced with fresh indications, updated formulat…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s “API push” isn’t just industrial policy—it’s written in patent filings.
If you want to understand where Russia’s pharmaceutical supply chain is headed, don’t start with press releases. Start with the paperwork.
A growing body of evidence sugge…

Europe is quietly rewriting the rules of generics—one procedural delay at a time.
In theory, patent systems are designed to balance two goals: reward innovation and keep markets competitive once exclusivity ends. In practice, the “divisional” patent ga…

Pharma patent litigation used to be a $50M inevitability.
Now, it’s increasingly a $5M choice.
That’s not a slogan—it’s the direction of travel highlighted in a recent DrugPatentWatch piece on cutting pharma patent litigation costs from roughly $50 mil…

PBMs don’t just “manage formularies.” They shape the economics of every drug launch, every contract renegotiation, and—quietly—every patient’s access decision.
If you’re a pharma executive, the last few years have made one thing painfully clear: rebate…

Mark Cuban’s Cost-Plus Pricing Isn’t Just a Pricing Story—It’s a Patent-Playbook Story
For years, the pharmaceutical industry has operated with a kind of unspoken logic: patents don’t only protect innovation—they also protect pricing power. And when a …

Should you file a provisional patent for your drug invention? The honest answer is: it depends—on your timeline, your evidence, and how you plan to protect value once the clock starts ticking.
In biotech and pharma, “provisional” can sound like a low-f…